Global CAR T-Cell Therapy Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch＇s in-depth investigation and research, the global CAR T-Cell Therapy market size will reach 3,856.34 Million USD in 2025 and is projected to reach 9,259.54 Million USD by 2032, with a CAGR of 13.33% (2025-2032). Notably, the China CAR T-Cell Therapy market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
CAR T-cell therapy, also known as chimeric antigen receptor T-cell therapy, is an innovative and personalized immunotherapy approach used in the treatment of certain types of cancer. It involves modifying a patient＇s own T cells, which are a type of immune cell, to express a synthetic receptor called a chimeric antigen receptor (CAR) on their surface. The CAR is designed to recognize and bind to specific proteins, known as antigens, found on cancer cells. Once the modified CAR T cells are infused back into the patient＇s body, they can identify and attack cancer cells that express the targeted antigen, effectively destroying the cancer cells. CAR T-cell therapy has shown remarkable success in the treatment of certain hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. It has provided new hope for patients who have exhausted other treatment options, and its efficacy continues to be investigated in clinical trials for various other types of cancers. CAR T-cell therapy represents a promising advancement in cancer treatment, harnessing the power of the patient＇s own immune system to fight and potentially eradicate cancer cells.
The major global suppliers of CAR T-Cell Therapy include Bristol Myers Squibb, Gilead Sciences, Novartis, Autolus, Janssen, JW Therapeutics, Beijing Immunochina Pharmaceuticals, Bioray Laboratories, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of CAR T-Cell Therapy. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global CAR T-Cell Therapy market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the CAR T-Cell Therapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of CAR T-Cell Therapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of CAR T-Cell Therapy Include:
Bristol Myers Squibb
Gilead Sciences
Novartis
Autolus
Janssen
JW Therapeutics
Beijing Immunochina Pharmaceuticals
Bioray Laboratories
CAR T-Cell Therapy Product Segment Include:
CD19
BCMA
CD19/CD22
Others
CAR T-Cell Therapy Product Application Include:
Non-Hodgkin Lymphoma
Multiple Myeloma
Acute Lymphoblastic Leukemia
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global CAR T-Cell Therapy Industry PESTEL Analysis
Chapter 3: Global CAR T-Cell Therapy Industry Porter's Five Forces Analysis
Chapter 4: Global CAR T-Cell Therapy Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global CAR T-Cell Therapy Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global CAR T-Cell Therapy Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, CAR T-Cell Therapy Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch＇s in-depth investigation and research, the global CAR T-Cell Therapy market size will reach 3,856.34 Million USD in 2025 and is projected to reach 9,259.54 Million USD by 2032, with a CAGR of 13.33% (2025-2032). Notably, the China CAR T-Cell Therapy market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
CAR T-cell therapy, also known as chimeric antigen receptor T-cell therapy, is an innovative and personalized immunotherapy approach used in the treatment of certain types of cancer. It involves modifying a patient＇s own T cells, which are a type of immune cell, to express a synthetic receptor called a chimeric antigen receptor (CAR) on their surface. The CAR is designed to recognize and bind to specific proteins, known as antigens, found on cancer cells. Once the modified CAR T cells are infused back into the patient＇s body, they can identify and attack cancer cells that express the targeted antigen, effectively destroying the cancer cells. CAR T-cell therapy has shown remarkable success in the treatment of certain hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. It has provided new hope for patients who have exhausted other treatment options, and its efficacy continues to be investigated in clinical trials for various other types of cancers. CAR T-cell therapy represents a promising advancement in cancer treatment, harnessing the power of the patient＇s own immune system to fight and potentially eradicate cancer cells.
The major global suppliers of CAR T-Cell Therapy include Bristol Myers Squibb, Gilead Sciences, Novartis, Autolus, Janssen, JW Therapeutics, Beijing Immunochina Pharmaceuticals, Bioray Laboratories, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of CAR T-Cell Therapy. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global CAR T-Cell Therapy market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the CAR T-Cell Therapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of CAR T-Cell Therapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of CAR T-Cell Therapy Include:
Bristol Myers Squibb
Gilead Sciences
Novartis
Autolus
Janssen
JW Therapeutics
Beijing Immunochina Pharmaceuticals
Bioray Laboratories
CAR T-Cell Therapy Product Segment Include:
CD19
BCMA
CD19/CD22
Others
CAR T-Cell Therapy Product Application Include:
Non-Hodgkin Lymphoma
Multiple Myeloma
Acute Lymphoblastic Leukemia
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global CAR T-Cell Therapy Industry PESTEL Analysis
Chapter 3: Global CAR T-Cell Therapy Industry Porter's Five Forces Analysis
Chapter 4: Global CAR T-Cell Therapy Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global CAR T-Cell Therapy Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global CAR T-Cell Therapy Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, CAR T-Cell Therapy Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 CAR T-Cell Therapy Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 CAR T-Cell Therapy Product by Type
- 1.2.1 CD19
- 1.2.2 BCMA
- 1.2.3 CD19/CD22
- 1.2.4 Others
- 1.3 CAR T-Cell Therapy Product by Application
- 1.3.1 Non-Hodgkin Lymphoma
- 1.3.2 Multiple Myeloma
- 1.3.3 Acute Lymphoblastic Leukemia
- 1.3.4 Other
- 1.4 Global CAR T-Cell Therapy Market Size Analysis (2020-2032)
- 1.5 CAR T-Cell Therapy Market Development Status and Trends
- 1.5.1 CAR T-Cell Therapy Industry Development Status Analysis
- 1.5.2 CAR T-Cell Therapy Industry Development Trends Analysis
- 2 CAR T-Cell Therapy Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 CAR T-Cell Therapy Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global CAR T-Cell Therapy Market Analysis by Country
- 4.1 Global CAR T-Cell Therapy Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global CAR T-Cell Therapy Revenue Analysis by Country (2020-2025)
- 4.1.2 Global CAR T-Cell Therapy Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.5 China CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.6 France CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.14 India CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa CAR T-Cell Therapy Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global CAR T-Cell Therapy Market Revenue by Key Suppliers (2021-2025)
- 5.2 CAR T-Cell Therapy Competitive Landscape Analysis and Market Dynamic
- 5.2.1 CAR T-Cell Therapy Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 CAR T-Cell Therapy Market Analysis by Type
- 6.1 Global CAR T-Cell Therapy Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global CAR T-Cell Therapy Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Bristol Myers Squibb
- 7.1.1 Bristol Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Bristol Myers Squibb CAR T-Cell Therapy Product Portfolio
- 7.1.3 Bristol Myers Squibb CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Gilead Sciences
- 7.2.1 Gilead Sciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Gilead Sciences CAR T-Cell Therapy Product Portfolio
- 7.2.3 Gilead Sciences CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Novartis
- 7.3.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Novartis CAR T-Cell Therapy Product Portfolio
- 7.3.3 Novartis CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Autolus
- 7.4.1 Autolus Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Autolus CAR T-Cell Therapy Product Portfolio
- 7.4.3 Autolus CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Janssen
- 7.5.1 Janssen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Janssen CAR T-Cell Therapy Product Portfolio
- 7.5.3 Janssen CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 JW Therapeutics
- 7.6.1 JW Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 JW Therapeutics CAR T-Cell Therapy Product Portfolio
- 7.6.3 JW Therapeutics CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Beijing Immunochina Pharmaceuticals
- 7.7.1 Beijing Immunochina Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Beijing Immunochina Pharmaceuticals CAR T-Cell Therapy Product Portfolio
- 7.7.3 Beijing Immunochina Pharmaceuticals CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Bioray Laboratories
- 7.8.1 Bioray Laboratories Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Bioray Laboratories CAR T-Cell Therapy Product Portfolio
- 7.8.3 Bioray Laboratories CAR T-Cell Therapy Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 CAR T-Cell Therapy Industry Chain Analysis
- 8.2 CAR T-Cell Therapy Product Downstream Application Analysis
- 8.2.1 Global CAR T-Cell Therapy Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global CAR T-Cell Therapy Revenue and Forecast by Application (2020-2032)
- 8.3 CAR T-Cell Therapy Typical Downstream Customers
- 8.4 CAR T-Cell Therapy Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
